Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.32 |
| ▸ | CPB1 | P15086 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61920 | 1.00 | CPB2 (0.32) | CPB2CPB1EPHX1 | |
| Pyrene SCHEMBL28035477 | 0.89 | PIN1 (0.35) | EPHX1 | |
| SCHEMBL5893971 | 0.87 | CPB2 (0.32) | CPB2CPB1 | |
| SCHEMBL5893967 | 0.87 | CPB2 (0.32) | CPB2CPB1 | |
| Hydrochloric Acid SCHEMBL31172342 | 0.85 | CPB2 (0.31) | CPB2CPB1 | |
| SCHEMBL16310139 | 0.84 | HDAC6 (0.34) | — | |
| SCHEMBL30611740 | 0.84 | CPB2 (0.33) | CPB2CPB1 | |
| SCHEMBL3378638 | 0.83 | CPB2 (0.34) | CPB2CPB1 | |
| Hydrochloric Acid SCHEMBL30634622 | 0.83 | CPB2 (0.34) | CPB2CPB1 | |
| SCHEMBL3378642 | 0.83 | CPB2 (0.34) | CPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3250191-B1 | TABLETS COMPRISING GLP-1 AGONIST AND ENTERIC COATING | NOVO NORDISK AS (DK) | 2024-01-17 | — | — | EP | claimed |
| CN-109922835-B | DCHBS active ester of PEG compound and application thereof | 诺和诺德股份有限公司 | 2023-08-04 | — | — | CN | claimed |
| EP-2637698-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2022-04-20 | — | — | EP | claimed |
| CN-107108714-B | GLP-1 derivatives and uses thereof | 诺和诺德股份有限公司 | 2022-02-08 | — | — | CN | claimed |
| US-11117947-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2021-09-14 | — | — | US | claimed |
| US-11034746-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2021-06-15 | — | — | US | claimed |
| US-10946074-B2 | GLP-1 derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2021-03-16 | — | — | US | claimed |
| US-10689429-B2 | Double-acylated GLP-1 compounds | NOVO NORDISK A/S (DK) | 2020-06-23 | — | — | US | claimed |
| US-10604554-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2020-03-31 | — | — | US | claimed |
| US-20200079834-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2020-03-12 | — | — | US | claimed |
| WO-2013167455-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2013-11-14 | — | — | WO | claimed |
| US-20130288960-A1 | Double-Acylated GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2013-10-31 | — | — | US | claimed |
| US-20120295847-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2012-11-22 | — | — | US | claimed |
| EP-1863839-B1 | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK AS (DK) | 2010-08-04 | — | — | EP | claimed |
| US-20090156478-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2009-06-18 | — | — | US | claimed |
| US-20080207507-A1 | Extended Glp-1 Compounds | NOVO NORDISK A/S (DK) | 2008-08-28 | — | — | US | claimed |
| EP-1863521-A1 | EXTENDED GLP-1 COMPOUNDS | Novo Nordisk A/S (DK) | 2007-12-12 | — | — | EP | claimed |
| EP-1863839-A2 | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2007-12-12 | — | — | EP | claimed |
| WO-2006097537-A2 | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-09-21 | — | — | WO | claimed |
| WO-2006097538-A1 | EXTENDED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-09-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207507-A1 | Extended Glp-1 Compounds | GLP1R, GIPR, IAPP | CPB2 2455/4885CPB1 1157/4885EPHX1 3005/4885 |
| US-20090156478-A1 | Acylated GLP-1 Compounds | GLP1R, GIPR, GCGR | CPB2 3200/4885CPB1 1837/4885EPHX1 3672/4885 |
| US-10604554-B2 | Double-acylated GLP-1 derivatives | GLP1R, GIPR, GPR119 | CPB2 3610/4885CPB1 3560/4885EPHX1 2733/4885 |
| US-20120295847-A1 | Acylated GLP-1 Compounds | GLP1R, GIPR, GCGR | CPB2 3200/4885CPB1 1837/4885EPHX1 3672/4885 |
| US-11117947-B2 | Double-acylated GLP-1 derivatives | GLP1R, SLC5A1, IAPP | CPB2 4393/4885CPB1 3963/4885EPHX1 3870/4885 |
| US-11034746-B2 | Double-acylated GLP-1 derivatives | GLP1R, SLC5A1, IAPP | CPB2 4353/4885CPB1 3969/4885EPHX1 3949/4885 |
| US-20130288960-A1 | Double-Acylated GLP-1 Derivatives | GLP1R, VIP, IAPP | CPB2 3334/4885CPB1 2694/4885EPHX1 3822/4885 |
| US-20200079834-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | GLP1R, SLC5A1, IAPP | CPB2 4393/4885CPB1 3963/4885EPHX1 3870/4885 |
| US-10689429-B2 | Double-acylated GLP-1 compounds | GLP1R, GIPR, GPR119 | CPB2 2080/4885CPB1 1356/4885EPHX1 2760/4885 |
| US-10946074-B2 | GLP-1 derivatives and uses thereof | GLP1R, DPP8, DPP7 | CPB2 1968/4885CPB1 1672/4885EPHX1 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.